Aquestive Therapeutics, Inc. (AQST): who owns it and who trades it
As of Nov 16, 2026, AQST insiders reported 17 open-market sales worth $2.4M and 2 purchases worth $99.3K in the last 12 months, with 32% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel Barber (CEO), with $1.3M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Aquestive Therapeutics
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AQST
185 funds and institutions reported AQST shares worth $301M at the end of Q2 2026, about 59% of the company. The largest holder is Bratton Capital Management, L.P. with 8.0%.
Funds and institutions (13F) 59%Everyone else 41%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bratton Capital Management, L.P. | 9.81M | 8.04% | $40.8M | No change |
| BlackRock, Inc. | 8.07M | 6.61% | $33.6M | +7% |
| Rtw Investments, LP | 7.43M | 6.09% | $30.9M | No change |
| Vanguard Capital Management LLC | 4.58M | 3.76% | $19.1M | +3% |
| Federated Hermes, Inc. | 3.11M | 2.55% | $12.9M | +6% |
| State Street Corp | 2.93M | 2.40% | $12.2M | +15% |
| Geode Capital Management, LLC | 2.62M | 2.15% | $10.9M | +9% |
| Samsara Biocapital, LLC | 2.50M | 2.05% | $10.4M | No change |
| Bank of America Corp | 1.67M | 1.37% | $6.9M | -31% |
| Sio Capital Management, LLC | 1.49M | 1.22% | $6.2M | -23% |
| Propel Bio Management, LLC | 1.44M | 1.18% | $6M | +103% |
| Wasatch Advisors LP | 1.39M | 1.14% | $5.8M | +58% |
| Two Sigma Investments, LP | 1.28M | 1.05% | $5.3M | +12% |
| Nuveen, LLC | 1.22M | 1.00% | $5.1M | +379% |
| Janney Montgomery Scott LLC | 1.11M | 0.91% | $4.6M | +2% |
| Wells Fargo & Company | 1.09M | 0.89% | $4.5M | +5% |
| Commonwealth Equity Services, LLC | 1.05M | 0.86% | $4.4M | -3% |
| Barclays PLC | 996,665 | 0.82% | $4.1M | +25% |
| Blue Owl Capital Holdings LP | 942,932 | 0.77% | $3.9M | -30% |
| Northern Trust Corp | 831,151 | 0.68% | $3.5M | +13% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AQST insiders reported $99.3K of open-market purchases and $2.4M of sales. 32% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Matthew W. Davis | Chief Development Office | Sale plan | 7,197 | $3.55 | $25.5K | Form 4 |
| Nov 10, 2026 | Richard J Daly | Director | Purchase | 1,200 | $3.53 | $4.2K | Form 4 |
| Nov 10, 2026 | Richard J Daly | Director | Purchase | 26,825 | $3.54 | $95.1K | Form 4 |
| Oct 15, 2026 | Daniel Barber | CEO | Sale plan | 25,000 | $4.22 | $106K | Form 4 |
| Sep 15, 2026 | Daniel Barber | CEO | Sale plan | 25,000 | $4.82 | $120K | Form 4 |
| Sep 9, 2026 | Sherry Korczynski | Chief Commercial Officer | Sale plan | 8,750 | $5.22 | $45.7K | Form 4 |
| Aug 17, 2026 | Daniel Barber | CEO | Sale plan | 25,000 | $4.29 | $107K | Form 4 |
| Jul 16, 2026 | Daniel Barber | CEO | Sale plan | 20,369 | $4.00 | $81.5K | Form 4 |
| Jul 15, 2026 | Daniel Barber | CEO | Sale plan | 4,631 | $4.03 | $18.7K | Form 4 |
| Jun 23, 2026 | Julie Krop | Director | Sale plan | 25,000 | $5.02 | $125K | Form 4 |
| Jun 15, 2026 | Daniel Barber | CEO | Sale plan | 25,000 | $4.16 | $104K | Form 4 |
| May 15, 2026 | Daniel Barber | CEO | Sale plan | 8,257 | $4.29 | $35.4K | Form 4 |
| Mar 10, 2026 | Peter E. Boyd | Chief People Officer | Sale | 29,814 | $4.17 | $124K | Form 4 |
| Mar 10, 2026 | Daniel Barber | CEO | Sale | 180,677 | $4.17 | $753K | Form 4 |
| Mar 10, 2026 | Lori J Braender | Chief Legal Officer | Sale | 40,102 | $4.17 | $167K | Form 4 |
| Mar 10, 2026 | Melina Cioffi | Vice president | Sale | 25,311 | $4.17 | $106K | Form 4 |
| Mar 10, 2026 | A Ernest Toth Jr | CFO | Sale | 58,254 | $4.17 | $243K | Form 4 |
| Mar 10, 2026 | Sherry Korczynski | Chief Commercial Officer | Sale | 15,741 | $4.17 | $65.6K | Form 4 |
| Mar 10, 2026 | Cassie Jung | Chief Operating Officer | Sale | 45,791 | $4.17 | $191K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Daniel Barber | President and CEO | – | $1.3M | Oct 15, 2026 |
| A Ernest Toth Jr | Chief Financial Officer | – | $243K | Mar 10, 2026 |
| Cassie Jung | Chief Operating Officer | – | $191K | Mar 10, 2026 |
| Lori J Braender | Chief Legal Officer | – | $167K | Mar 10, 2026 |
| Julie Krop | Director | – | $125K | Jun 23, 2026 |
| Peter E. Boyd | Chief People Officer | – | $124K | Mar 10, 2026 |
| Sherry Korczynski | Chief Commercial Officer | – | $111K | Sep 9, 2026 |
| Melina Cioffi | SVP, Regulatory Affairs | – | $106K | Mar 10, 2026 |
| Richard J Daly | Director | $99.3K | – | Nov 10, 2026 |
| Matthew W. Davis | Chief Development Officer | – | $25.5K | Nov 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AQST short interest
Very high short interest. 23.3% of AQST shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 95%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 29.32M AQST shares were sold short, 23.3% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 13.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 29.32M | 23.33% | +6% | 2.21M | 13.2 |
| Oct 15, 2026 | 27.60M | 21.99% | -4% | 1.99M | 13.9 |
| Sep 30, 2026 | 28.75M | 22.90% | +6% | 2.20M | 13.1 |
| Sep 15, 2026 | 27.16M | 21.64% | +7% | 2.30M | 11.8 |
| Aug 31, 2026 | 25.48M | 20.30% | +22% | 3.56M | 7.2 |
| Aug 14, 2026 | 20.95M | 16.69% | +16% | 4.04M | 5.2 |
| Jul 31, 2026 | 18.05M | 14.79% | +8% | 2.02M | 8.9 |
| Jul 15, 2026 | 16.67M | 13.66% | +4% | 1.53M | 10.9 |
| Jun 30, 2026 | 16.00M | 13.11% | +8% | 3.03M | 5.3 |
| Jun 15, 2026 | 14.80M | 12.12% | -3% | 1.55M | 9.6 |
| May 29, 2026 | 15.24M | 12.49% | +1% | 1.41M | 10.8 |
| May 15, 2026 | 15.03M | 12.32% | -3% | 2.02M | 7.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aquestive Therapeutics company events
Aquestive Therapeutics filed 18 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Nov 3, 2026ResultsReleased financial results. Filing
- Oct 19, 2026RulesChanged its bylaws or articles. Filing
- Oct 15, 2026AnnouncementShared information with investors. Filing
- Oct 14, 2026AgreementAquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients with epilepsy, subject to… Filing
- Sep 29, 2026LeadershipAquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Filing
- Sep 25, 2026AnnouncementShared information with investors. Filing
- Sep 17, 2026AnnouncementThe Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 10, 2026AnnouncementAquestive Therapeutics, Inc. issued a press release announcing the results from its human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film, conducted in support of the Company’s planned resubmission of its New Drug Application to the U.S. Food and… Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 13, 2026AgreementAquestive Therapeutics, Inc. entered into a five-year term loan facility of up to $150.0 million, consisting of a term loan in an of $55.0 million that was funded on the Effective Date, a term loan in an of $20.0 million available subject to certain terms and conditions, a term loan in an of $25.0… Filing
- Mar 30, 2026AnnouncementShared information with investors. Filing
- Mar 20, 2026LeadershipAquestive Therapeutics, Inc. and Lori J. Braender, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of the Company, agreed that Ms. Braender will step down from her Chief Legal Officer and Chief Compliance Officer roles and will no longer serve as an executive officer of the… Filing
- Mar 4, 2026AgreementAquestive Therapeutics, Inc. entered into Amendment No. 1 to the Purchase and Sale Agreement, dated August 13, 2025, with funds managed by RTW Investments, LP. Filing
- Feb 26, 2026AnnouncementShared information with investors. Filing
- Feb 2, 2026AnnouncementShared information with investors. Filing
- Jan 9, 2026AnnouncementAquestive Therapeutics, Inc. issued a press release announcing the receipt of a notice from the U.S. Food and Drug Administration (FDA) that, as part of its ongoing review, the FDA had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aquestive Therapeutics financials
Famous investors that hold AQST
3 of the 50 well-known investors we track reported holding AQST in their latest 13F filing. The largest position is Ken Griffin's, worth $3.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 809,853 | $3.7M | 0.0% | +79% |
| Israel Englander · Millennium Management | Q3 2026 | 687,058 | $3.2M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 558,472 | $2.6M | 0.0% | +34% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AQST in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 7, 2026 | Bass Edward P | 13G | 7.5% |
| Oct 7, 2026 | Bass Edward P | 13G | 7.5% |
| Oct 7, 2026 | BRATTON DOUGLAS K | 13G/A | 0.6% |
| Oct 7, 2026 | BRATTON DOUGLAS K | 13G/A | 0.6% |
Questions about Aquestive Therapeutics, Inc. (AQST) stock
Who owns the most AQST stock?
The largest reported owner of Aquestive Therapeutics, Inc. (AQST) is Bratton Capital Management, L.P., with 8.0% of the company. In total, 185 funds and institutions reported holding AQST at the end of Q2 2026, together about 59% of the shares. See the largest owners.
Are AQST insiders buying or selling?
In the last 12 months, AQST insiders reported 2 open-market purchases worth $99.3K and 17 sales worth $2.4M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in AQST?
As of Oct 30, 2026, 29.32M AQST shares were sold short, 23.3% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 13.2 trading days (days to cover). See the history.
Which famous investors hold AQST?
3 of the 50 well-known investors we track reported AQST in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $3.7M. See all holders.
Executive pay
Aquestive Therapeutics's chief executive was paid a total of $3.5M for the year ended Dec 31, 2025, down 16% from $4.2M the year before. In the last 12 months, Aquestive Therapeutics's executives and directors bought $99.3K of stock on the open market and sold $2.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.